Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H4O2 |
Molecular Weight | 72.0627 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1CCO1
InChI
InChIKey=VEZXCJBBBCKRPI-UHFFFAOYSA-N
InChI=1S/C3H4O2/c4-3-1-2-5-3/h1-2H2
Molecular Formula | C3H4O2 |
Molecular Weight | 72.0627 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Propiolactone (or beta-propiolactone) is a disinfectant used in vapor form to sterilize vaccines, grafts, blood plasma, surgical instruments. It has been used against bacteria, fungi, and virus. Propiolactone was first commercially available in the United States in 1958 but then was withdrawn because it was discovered that compound was a human carcinogen. The results have shown the generation of tumors in several tissues and from different administration routes. Propiolactone is a direct-acting alkylating agent that reacts with polynucleotides and DNA, mainly at N7 of guanine and N1 of adenine, to form carboxyethyl derivatives.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation. | 1989 |
|
beta-Propiolactone. | 2002 |
|
Platelet adhesion onto segmented polyurethane surfaces modified by carboxybetaine. | 2003 |
|
Development of a non-immunising, paraspecific vaccine from attenuated pox viruses: a new type of vaccine. | 2003 Jan |
|
The effect of chemical inactivation of bovine viral diarrhea virus with beta-propiolactone and binary ethyleneimine on plasma proteins and coagulation factors. | 2004 |
|
Establishment of batch 4 of the Biological Reference Preparation (BRP) for rabies vaccine (inactivated) for veterinary use. | 2004 Dec |
|
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. | 2004 Dec 10 |
|
Vero-cell rabies vaccine produced using serum-free medium. | 2004 Dec 9 |
|
In vitro inactivation of the rabies virus by ascorbic acid. | 2004 Jan |
|
Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. | 2004 Jun |
|
[Direct identification of Ophiogon japonicus (Thunb.)Ker-Gawl. from its confusable varieties by second derivative FTIR spectroscopy combined with statistics]. | 2004 Sep |
|
Molecular advances in the cell biology of SARS-CoV and current disease prevention strategies. | 2005 Apr 15 |
|
SARS vaccine protective in mice. | 2005 Aug |
|
Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. | 2005 Aug 15 |
|
Ru-catalyzed alkene-alkyne coupling. Total synthesis of amphidinolide P. | 2005 Dec 21 |
|
Anticomplementary activity of equine whole IgG antivenoms: comparison of three fractionation protocols. | 2005 Jan |
|
Reactivity of lactones and GHB formation. | 2005 Jan 21 |
|
A kinetic approach to the alkylating potential of carcinogenic lactones. | 2005 Jul |
|
[Conditions for SARS-CoV cultivation and inactivation]. | 2005 Jun |
|
Profile of animal bite cases in Pune. | 2005 Mar |
|
[Development of purified HFRS bivalent vaccine]. | 2005 Mar |
|
Modulation of macrophage functions by sheeppox virus provides clues to understand interaction of the virus with host immune system. | 2005 Mar 22 |
|
Role of activation function domain-1, DNA binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid receptor-antagonist complexes. | 2005 Mar 8 |
|
Dengue type 3 virus, Saint Martin, 2003-2004. | 2005 May |
|
Ophiopojaponin D, a new phenylpropanoid glycoside from Ophiopogon japonicus Ker-Gawl. | 2005 Nov |
|
Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. | 2006 Dec |
|
Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. | 2006 Feb 13 |
|
Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. | 2006 Jan |
|
Structures of heterogeneous proton-bond dimers with a high dipole moment monomer: covalent vs electrostatic interactions. | 2006 May 11 |
|
Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. | 2007 |
|
Frequencies of mutagen-induced coincident mitotic recombination at unlinked loci in Saccharomyces cerevisiae. | 2007 Mar 1 |
|
Enzymatic synthesis of poly(hydroxyalkanoates) in ionic liquids. | 2007 Nov 1 |
|
Efficiency of Matricaria chamomilla CH12 and number of doses of rabies vaccine on the humoral immune response in cattle. | 2008 Dec |
|
Development of stable influenza vaccine powder formulations: challenges and possibilities. | 2008 Jun |
|
Chemical addressability of ultraviolet-inactivated viral nanoparticles (VNPs). | 2008 Oct 2 |
|
Serological response in cattle immunized with inactivated oil and Algel adjuvant vaccines against infectious bovine rhinotracheitis. | 2009 Apr |
|
Matrix photochemistry, photoelectron spectroscopy, solid-phase structure, and ring strain energy of beta-propiothiolactone. | 2009 Apr 16 |
|
Pandemic influenza vaccines - the challenges. | 2009 Dec |
|
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. | 2009 Jan |
|
Poly(lactide-co-glycolide) microspheres: a potent oral delivery system to elicit systemic immune response against inactivated rabies virus. | 2009 Mar 26 |
|
From where did the 2009 'swine-origin' influenza A virus (H1N1) emerge? | 2009 Nov 24 |
|
Induction of cell-cell fusion by ectromelia virus is not inhibited by its fusion inhibitory complex. | 2009 Sep 29 |
|
Safety and efficacy of an inactivated Carbopol-adjuvanted goose haemorrhagic polyomavirus vaccine for domestic geese. | 2010 Apr |
|
Use of the hemagglutinating virus of Japan (HVJ) envelope as a versatile delivery system for nucleic acids and proteins to leukocytes in vitro. | 2010 Apr |
|
Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India. | 2010 Aug 25 |
|
Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria. | 2010 Jul 27 |
|
Molecular identification of the vaccine strain from the inactivated oil emulsion H9N2 low pathogenic avian influenza vaccine. | 2010 Jun |
|
Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. | 2010 Jun 22 |
|
GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. | 2010 Nov 3 |
|
Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. | 2010 Oct |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:25:36 GMT 2025
by
admin
on
Mon Mar 31 18:25:36 GMT 2025
|
Record UNII |
6RC3ZT4HB0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C45187
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
||
|
IARC | beta-Propiolactone | ||
|
NCI_THESAURUS |
C606
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BETA-PROPIOLACTONE
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
21626
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
DTXSID8021197
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
3495
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
D011420
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
1311565
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | RxNorm | ||
|
6RC3ZT4HB0
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
49073
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
SUB10109MIG
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
811
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
1749
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
m9204
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000081358
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
2365
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
DB09348
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
200-340-1
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200627
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
57-57-8
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY | |||
|
C44339
Created by
admin on Mon Mar 31 18:25:36 GMT 2025 , Edited by admin on Mon Mar 31 18:25:36 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |